-
Views
-
Cite
Cite
Pascal Rigaudy, Cross-boundary Cancer Studies at the University of Tokyo: Oncology in Asian Countries: Clinical Development Challenges and Opportunities, Japanese Journal of Clinical Oncology, Volume 44, Issue suppl_1, February 2014, Pages i54–i59, https://doi.org/10.1093/jjco/hyt207
- Share Icon Share
Extract
LECTURER PROFILE
Pascal Rigaudy gained his Pharm.D and PhD from Paris University and MBA from INSEAD. Following a career in research, with PhD work undertaken at the Gustave Roussy Institute in France and post-doctoral work on oncogenes and tumor suppressor genes at the Salk Institute in the USA, Rigaudy subsequently joined the pharmaceutical industry. He has spent 5 years at Novartis and 14 years at Sanofi, working in different disease areas, including hematology, gynecological cancers, gastrointestinal, breast, lung and prostate cancers. He has worked with Asian countries since 2003, and currently serves as Head of Oncology Business Unit for Japan & Pacific Region.
ONCOLOGY IN ASIAN COUNTRIES: CLINICAL DEVELOPMENT CHALLENGES AND OPPORTUNITIES
Introduction to Sanofi
Sanofi is one of the largest pharmaceutical companies in the world, with 110 000 employees in 100 countries. In 2011 the company had net sales of €33.4 billion, representing 3.2% growth on a reported basis, year-on-year. The current Sanofi was formed in 2004 when Sanofi-Synthélabo acquired Aventis, last year the company name was changed to Sanofi. Through a large number of mergers and acquisitions since 1973, the company has grown to its current size. Most recently, Sanofi acquired Genzyme in 2011.